A Phase III, multicenter, randomized, placebo-controlled study of MPDL3280A (Anti-PD-L1 antibody) in combination with NAB Paclitaxel compared with placebo with NAB Paclitaxel for patients with previsouly untreated metastatic triple negative breast cancer

The following trials are actively recruiting patients with breast cancer and are listed with the study identifier number.

IMpassion 130 (WO29522):
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer.
This study is being conducted to determine the efficacy and safety in using Atezolizumab in combination with nab-paclitaxel in treating patients with metastatic breast cancer. The safety of single-agent nab-paclitaxel has been determined in previous studies of patients with metastatic breast cancer, and preliminary data shows the use of Atezolizumab is safe to use in combination with chemotherapy.